Cargando…

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma

Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The research on predictive biomarkers in metastatic CRC (mCRC) mainly focused on the identification of bioma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rachiglio, Anna Maria, Sacco, Alessandra, Forgione, Laura, Esposito, Claudia, Chicchinelli, Nicoletta, Normanno, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400741/ https://www.ncbi.nlm.nih.gov/pubmed/36046264 http://dx.doi.org/10.37349/etat.2020.00004

Ejemplares similares

Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
por: Carotenuto, Marianeve, et al.
Publicado: (2022)

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology
por: Roma, Cristin, et al.
Publicado: (2013)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
por: Salvatore, Lisa, et al.
Publicado: (2017)

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022)

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
por: De Luca, Antonella, et al.
Publicado: (2020)

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
por: Martinelli, E, et al.
Publicado: (2017)

RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
por: Gallo, Marianna, et al.
Publicado: (2018)

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting
por: Barone, Carlo, et al.
Publicado: (2014)

Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal carcinoma
por: Zhao, Hong, et al.
Publicado: (2017)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

Immunotherapy regimens for metastatic colorectal carcinomas
por: Bashir, Babar, et al.
Publicado: (2017)

Genomic landscape of metastatic colorectal cancer
por: Haan, Josien C., et al.
Publicado: (2014)

Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor γ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome
por: Pancione, Massimo, et al.
Publicado: (2010)

Correction: Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor γ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome
por: Pancione, Massimo, et al.
Publicado: (2011)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

Integrative Genomic and Transcriptomic Characterization of Matched Primary and Metastatic Liver and Colorectal Carcinoma
por: Roessler, Stephanie, et al.
Publicado: (2015)

Colorectal Cancer: Prevention and Management of Metastatic Disease
por: Sugarbaker, Paul H.
Publicado: (2014)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine
por: Dotolo, Serena, et al.
Publicado: (2021)

Finding a New Prognostic Biomarker for Metastatic Colorectal Cancer
por: Kim, Hungdai
Publicado: (2012)

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
por: Volovat, Simona-Ruxandra, et al.
Publicado: (2022)

Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
por: Puccini, Alberto, et al.
Publicado: (2022)

The role of biomarker in later-line treatment for metastatic colorectal cancer
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Veillonella Bacteremia in a Patient With Metastatic Colorectal Carcinoma
por: Karki, Sailesh, et al.
Publicado: (2023)

TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma
por: Maddalena, Francesca, et al.
Publicado: (2017)

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer
por: Capalbo, Carlo, et al.
Publicado: (2019)

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gempca8gchktt3ogd02p7lphrm